BGDO | Belgian Group of Digestive Oncology

  • Plein écran
  • Ecran large
  • Ecran étroit
  • Increase font size
  • Default font size
  • Decrease font size

Magnet

E-mail Print PDF

A national randomised multi-centre trial to assess the effect of oral magnesium supplementation on the kinetics of magnesium wasting induced by EGFR targeted antibody therapy for colorectal carcinoma.

Oral supplementation with magnesium salts may prevent and/or significantly improve the magnesium wasting induced by EGFR-targeted antibody therapy in colorectal cancer.

Study objective :
• To evaluate the efficacy and tolerability of magnesium gluconate 3 g bid. given orally to modulate magnesium wasting in patients with colorectal cancer treated with EGFR targeted antibody therapy.
• To evaluate the efficacy and tolerability of magnesium gluconate 3 g six times per day compared to 3 g bid. given orally to modulate magnesium wasting in patients with colorectal cancer with grade 1 hypomagnesemia induced by EGFR targeted antibody therapy.

Planned accrual: 160 patients
Actual date of 1st inclusion : Oct 2007
End of inclusion : July 2013

180 patients were enrolled in 15 of the actively recruiting centers.